Already known
The role of bevazicumab remains unclear in the neoadjuvant and adjuvant
settings. In metastatic breast cancer, it provides some modest improvement
in outcome, but FDA approval may still be withdrawn for this indication.
What these studies showed
In the neoadjuvant setting for hormone receptorpositive (HR +) patients,
bevacizumab improved pathologic complete response (pCR). In triplenegative
breast cancer (TNBC) patients in the GeparQuinto study, bevacizumab
a 9% advantage for pCR. In the RIBON–2 trial of second-line
chemotherapy with bevacizumab, there was a significant progression-free
survival benefit and a trend for overall survival benefit for the
TNBC patients.
Next steps
Adjuvant trials are ongoing, including BETH , which is studying
the effects of bevacizumab plus chemotherapy plus trastuzumab in
human epidermal growth factor receptor 2-positive (HER2+) patients,
and BEATRICE , which is evaluating the addition of bevacizumab to
standard chemotherapy in patients with TNBC.
